- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03659734
Motivational Interviewing and Guided Opioid Tapering Support to Promote Postoperative Opioid Cessation
December 16, 2023 updated by: Jennifer Hah, Stanford University
Randomized Controlled Trial to Evaluate the Relative Efficacy of Motivational Interviewing and Guided Opioid Tapering Support vs. Enhanced Usual Care to Promote Opioid Cessation After Orthopedic Surgery
The purpose of this study is to evaluate the relative efficacy of enhanced usual care versus motivational interviewing and guided opioid tapering support to promote opioid cessation after total hip or knee replacement surgery.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
450
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Planning to undergo surgery
- English speaking
- Ability and willingness to complete questionnaires and assessments
- Scheduled for total hip, knee, or shoulder replacement
- Preoperative opioid use and opioid use 14 days after surgery to increase the likelihood of delayed opioid cessation.
- Not under the care of a current pain management provider
Exclusion Criteria:
- Any conditions causing inability to complete assessments
- Known pregnancy
- Elevated suicidality
- Enrollment in conflicting perioperative trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Motivational Interviewing and Guided Opioid Tapering Support
|
Following surgery, participants will undergo motivational interviewing with a trained member of the study staff.
These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
|
Experimental: Enhanced Usual Care
|
Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use.
These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Opioid Cessation
Time Frame: Through study completion, an average of 1 year
|
Time to opioid cessation between the two groups will be analyzed using survival analysis
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid Misuse
Time Frame: Through study completion, an average of 1 year
|
Participant score on the Current Opioid Misuse Measure and prescription information obtained via CURES 2.0 will be used to assess opioid misuse behaviors.
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jennifer Hah, MD, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2019
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
April 10, 2018
First Submitted That Met QC Criteria
September 4, 2018
First Posted (Actual)
September 6, 2018
Study Record Updates
Last Update Posted (Actual)
December 19, 2023
Last Update Submitted That Met QC Criteria
December 16, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-43163
- 1R01DA045027-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Cessation
-
Stanford UniversityCompletedOpioid CessationUnited States
-
University of HoustonWithdrawnSmoking | Smoking Cessation | Opioid Use | Opioid Abuse | Smoking, TobaccoUnited States
-
West Virginia UniversityNational Institute on Drug Abuse (NIDA); PfizerCompletedSmoking Cessation | Opioid Related DisordersUnited States
-
University of Maryland, BaltimoreCompletedSmoking Cessation | HIVKenya
-
University of MinnesotaCompletedSmoking Cessation | Tobacco CessationUnited States
-
Uppsala UniversityKarolinska Institutet; The Swedish Research Council; Region Stockholm; Swedish... and other collaboratorsTerminatedSmoking Cessation | Tobacco CessationSweden
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Food and Health Bureau, Hong Kong; Queen... and other collaboratorsCompletedSmoking Cessation | Tobacco Use CessationHong Kong
-
Centre for Addiction and Mental HealthCompletedSmoking Cessation | Tobacco Use CessationCanada
-
SanofiCompletedSmoking Cessation | Tobacco Use CessationUnited States, Canada
-
University of California, Los AngelesNYU Langone Health; Olive View-UCLA Education & Research InstituteEnrolling by invitationSmoking Cessation | Tobacco Use CessationUnited States
Clinical Trials on Motivational Interviewing and Guided Opioid Tapering Support
-
Medical University of ViennaNational Bank of AustriaUnknownDiabetes Mellitus, Type 1Austria
-
University of Texas at AustinUnknownSepsis | Shock | Critical Illness | Shock, Septic | Respiratory Failure | Chronic Disease | Respiratory Distress Syndrome, Adult | Shock, HypovolemicUnited States
-
VA Office of Research and DevelopmentCompletedPsychotic Disorders | Bipolar Disorder | UnemploymentUnited States
-
Washington State UniversityUnited States Department of DefenseRecruitingMild Cognitive Impairment | Subjective Cognitive ComplaintsUnited States
-
Johns Hopkins UniversityZanvyl and Isabelle Krieger FundCompleted
-
York UniversityRyerson University; University of Massachusetts, AmherstCompletedAnxiety Disorders | Generalized Anxiety DisorderCanada
-
Stanford UniversityCompletedOpioid CessationUnited States
-
Boston UniversityThe Miriam Hospital; Harvard School of Public Health (HSPH); Boston Housing AuthorityCompletedTobacco CessationUnited States
-
Center for Social Innovation, MassachusettsNational Institute of Mental Health (NIMH); National Institutes of Health (NIH) and other collaboratorsCompletedHIV/AIDS | Substance Use Disorders | Chronic Mental DisorderUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity | OverweightUnited States